Remus Pharmaceuticals IPO Date, GMP, Review, Price, Form & Market Lot Details

The Remus Pharmaceuticals IPO has begun on 17 May 2023. It will close on 19 May 2023. The Total IPO Size is 47.69 Crore. The company set its IPO price is 1150-1229 Rs Per Share. Basically, There are three basic categories in Remus Pharmaceuticals IPO Subscription 1) QIB 2) Non-Institutional Investors 3) Retail Individual Investors (RIIs)

Remus Pharmaceuticals is established in 2015.

Remus Pharmaceuticals is engaged marketing & distribution of finished formulations of pharmaceutical drugs. They also deals in API (Active Pharmaceutical Ingredient). They also provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.

Their client are spread in more than 20 countries. They have product portfolio consists of 429 products as on 31 January,2023.

Check :- Upcoming SME IPO 2023


There are no listed companies in India.

Remus Pharmaceuticals IPO Promotors

Name of the Promoter No. of Shares held Average cost of Acquisition (in ₹ )
Arpit Deepakkumar Shah 2,50,000 0.1000
Roma Vinodbhai Shah 2,50,000 0.1000
Swapnil Jatinbhai Shah 2,50,000 0.0620
Anar Swapnil Shah 2,50,000 9.4460
Total Pre Issue 10,00,000 (92.16%)

* The company gives a bonus in the year of March 28, 2023 ( Ratio: 99:1 means 99 Bonus Equity Shares for 1 equity share).

Remus Pharmaceuticals IPO Date, Details & Price Band

IPO Opening Dates 17 May 2023
IPO Closing Dates 19 May 2023
Price Band 1150-1229 Rs Per Share
Fresh issue 47.69 Crore
Total IPO size 47.69 Crore
Minimum bid (lot size) 100 Shares
Face Value 10 INR Per Share
QIB 50%
Non-Institutional 15%
Retail Allocation 35%
Listing On NSE SME

Remus Pharmaceuticals IPO Market Lot

The Remus Pharmaceuticals IPO minimum market lot is 100 shares With 1,22,900 ₹ Amount per application.

Lot No of Shares Amount
Minimum 1 100 1,22,900 Rs
Maximum 1 100 1,22,900 Rs
S-HNI (Min) 2 200 2,45,800 Rs

Restated Financial Record of the three year (Amt. in Lakhs)

Total Assets Total Revenue Profit After Tax
31-Mar-21 1,104.96 1,922.45 102.58
31-Mar-22 1,590.93 2,543.71 338.57
31-Dec-22 3,352.96 3,361.20 643.90
EPS(₹) NAV(₹) RoNW (%) borrowings (Lakhs)
31-Mar-21 10.26 30.46 33.68 27.89
31-Mar-22 33.86 64.32 52.64 19.17
31-Dec-22 64.35 157.79 37.61 947.45

Remus Pharmaceuticals IPO GMP Grey Market Premium

Remus Pharmaceuticals IPO GMP Grey market premium has been started today. Check Latest Remus Pharmaceuticals IPO GMP Grey market premium, Kostak Rates and Subject to Sauda Price here.

Remus Pharmaceuticals IPO Prospectus

Remus Pharmaceuticals IPO
DRHP Download
RHP Download

Remus Pharmaceuticals IPO Reviews

Angel Broking – Update Soon
Choice Broking – Update Soon
Prabhudas Lilladher – Update Soon

Remus Pharmaceuticals IPO Form Download

Remus Pharmaceuticals IPO is available on NSE Website as well as on our Portal. Please click here Remus Pharmaceuticals IPO form Download.

Remus Pharmaceuticals IPO Allotment Date & Details

Allotment Date 24 May 2023
Initiation of refunds 25 May 2023
Transfer of shares to Demat accounts 26 May 2023
Listing Date 29 May 2023
Check Allotment Status Click here

Registrar of Remus Pharmaceuticals IPO

SEBI Registration Number: INR000004058
Address: C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai,
Maharashtra, India – 400 083.
Tel. Number: +91 810 811 4949 Fax- +91 22 4918 6195
Email Id: [email protected]
Investors Grievance Id: [email protected]
Contact Person: Shanti Goapalkrishnan
CIN: U67190MH1999PTC118368

Remus Pharmaceuticals Contact Details

Remus Pharmaceuticals Limited
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli bopal Road, Ahmedabad – 380054
Phone: +079- 2999 9857
Email: [email protected]

Remus Pharmaceuticals IPO Lead Managers

SEBI Registration Number: INM000012917
Address: 807, Phoenix, Opp. Girish Cold Drinks, Near Vijay Cross Roads, Navrangpura,
Ahmedabad -380009, Gujarat.
Telephone Number: 079 4840 5357
Email Id: [email protected]
Investors Grievance Id: [email protected]
Contact Person: Mr. Nikhil Shah
CIN: U67190GJ2020PTC114322

Leave a Reply